10-K/A: America Great Health Files Amended 10-K, Reports Improved Financials

America Great Health files an amendment to its annual report, showcasing increased sales and reduced losses for the fiscal year ended June 30, 2023.

Summary

• America Great Health filed an amendment to its annual report on Form 10-K for the fiscal year ended June 30, 2023.
• The amendment includes an updated report from the independent auditor and certifications from the CEO and CFO.
• Sales increased to $204,309 in 2023 from $104,648 in 2022 due to the launch of new nutrition supplements.
• Cost of goods sold decreased significantly to $35,720 in 2023 from $1,588,453 in 2022 due to a return of defective products to the vendor.
• Gross profit improved to $168,588 in 2023 from a loss of $1,483,805 in 2022.
• Operating expenses decreased to $661,232 in 2023 from $3,250,293 in 2022 due to reduced payroll, rent, advertising, and professional expenses.
• The net loss decreased to $777,341 in 2023 from $4,924,936 in 2022, primarily due to lower cost of goods sold and operating expenses.
• The company had a cash balance of $54,150 as of June 30, 2023, and a working capital deficit of $2,912,469.
• The company's accumulated deficit was $9,183,110 as of June 30, 2023.
• The company's independent auditor has raised concerns about the company's ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document shows some positive trends in revenue and cost reduction, but the company's financial position is still weak, with a going concern warning and reliance on shareholder loans. The sentiment is neutral to slightly negative.

Positives

• The company experienced a significant increase in sales due to the introduction of new nutrition supplements.
• The company successfully reduced its cost of goods sold by returning defective products.
• The company's operating expenses were significantly reduced due to cost-cutting measures.
• The company's net loss was substantially reduced compared to the previous year.

Negatives

• The company has a significant working capital deficit of $2,912,469.
• The company has a large accumulated deficit of $9,183,110.
• The company's independent auditor has raised concerns about its ability to continue as a going concern.
• The company's cash balance is low at $54,150.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and lack of liquidity.
• The company is dependent on loans and advances from its majority shareholder for working capital.
• The company has material weaknesses in its internal control over financial reporting.
• The company's shares are subject to the penny stock rule, which may restrict trading.

Future Outlook

The company is raising additional capital to achieve profitable operations and intends to finance operating costs with existing cash and advances from the current majority shareholder. The company is also planning to make additional acquisitions in the health industry.

Management Comments

• Management believes that the company might be able to acquire some good growth companies and bring good values to our stockholders.
• Management's mission is to invest in innovative technologies integrated with business development in the healthcare ecosystem.
• Management is focused on protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy, and re-generational medicine and supplements manufacturing and sales.

Industry Context

The company is operating in the health industry, which is experiencing rapid growth in the Asia Pacific region due to improved living standards and increased demand for healthcare products and services. The company is also focused on innovative technologies such as protein and peptide small molecular drugs, AI cloud computing, and cell therapy, which are areas of significant interest and investment in the healthcare sector.

Comparison to Industry Standards

• The company's financial performance shows improvement compared to the previous year, but it is still operating at a loss.
• The company's gross profit margin has improved significantly due to the decrease in cost of goods sold.
• The company's operating expenses are still high relative to its revenue, indicating a need for further cost control.
• The company's cash balance is low, which is a concern for its ability to continue operations.
• Compared to other small biotech companies, America Great Health's financial situation is precarious, with a significant accumulated deficit and reliance on shareholder loans.
• Many small biotech companies are in a similar position, but the lack of a clear path to profitability and the going concern warning from the auditor are significant concerns.
• The company's focus on innovative technologies is aligned with industry trends, but it needs to demonstrate its ability to commercialize these technologies and generate revenue.

Related Party Transactions

• During the year ended June 30, 2023, the company's current majority shareholder advanced $224,423 to the company as working capital and the company repaid $373,140 to the shareholder.
• As of June 30, 2023, the company owed its current majority shareholder and other related parties $425,142.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to continue as a going concern and the potential for further dilution.
• Employees may be affected by the company's cost-cutting measures and the uncertainty surrounding its future.
• Customers may be impacted by the company's ability to deliver products and services if its financial situation does not improve.
• Suppliers may be concerned about the company's ability to pay its debts.
• Creditors may be at risk of not being repaid if the company's financial situation does not improve.

Next Steps

• The company intends to raise additional capital to achieve profitable operations.
• The company plans to make additional acquisitions in the health industry.
• The company will continue to focus on research and development of innovative technologies.

Key Dates

Keywords

financial results, nutrition supplements, cost of goods sold, operating expenses, net loss, going concern, internal control, penny stock, healthcare, biotechnology